Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lesson from Lilly’s Zyprexa Settlement: Be Proactive In Monitoring Sales Reps

Executive Summary

Companies might shield themselves from claims of off-label drug marketing by adopting oversight procedures mandated in Lilly's corporate integrity agreement with HHS

You may also be interested in...



Seroquel Marketing Plan Included “Spinning The Data, aka Lilly”

Plantiffs attorneys allege that AstraZeneca internal documents reveal intense effort to imitate competitors, placate study investigators.

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Lilly’s Legal Division Steers Firm Through Rough Seas Of Civil, Patent Cases

Set in a campus-like complex in downtown Indianapolis, Lilly projects a calm, unruffled atmosphere. A water fountain bubbles in front of the administrative building. Windows line the building's two-story lobby, filling the place with light. In front of the reception desk there is a display on the history of insulin, which Lilly first brought to market in 1923. And a museum with relics of the company's 133-year history stands behind it

Related Content

Topics

UsernamePublicRestriction

Register

PS050911

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel